Division of Vascular and Endovascular Surgery, Beth Israel Deaconess Medical Center, Boston, Mass.
Division of Vascular and Endovascular Surgery, Beth Israel Deaconess Medical Center, Boston, Mass.
J Vasc Surg. 2018 Feb;67(2):442-448. doi: 10.1016/j.jvs.2017.05.108. Epub 2017 Jul 26.
Preoperative type and cross are often routinely ordered before elective endovascular aneurysm repair (EVAR), but the cost of this practice is high, and transfusion is rare. We therefore aimed to stratify patients by their risk of transfusion to identify a cohort in whom a type and screen would be sufficient.
We queried the targeted vascular module of the National Surgical Quality Improvement Program (NSQIP) for all elective EVARs from 2011 to 2015. We included only infrarenal aneurysms and excluded ruptured aneurysms and patients transfused within 72 hours preoperatively. Two-thirds of the cases were randomly assigned to a model derivation cohort and one third to a validation cohort. We created and subsequently validated a risk model for transfusion within the first 24 hours of surgery (including intraoperatively), using logistic regression.
Between 2011 and 2015, there were 4875 patients who underwent elective infrarenal EVAR, only 221 (4.5%) of whom received a transfusion within 24 hours of surgery. The frequency of transfusion during the study period declined monotonously from 6.5% in 2011 to 3.2% in 2015. The factors independently associated with transfusion were preoperative hematocrit <36% (odds ratio [OR], 3.4 [95% confidence interval, 2.1-5.4]; P < .001), aortic diameter (per centimeter increase: OR, 1.2 [1.03-1.4]; P = .02), preoperative dependent functional status (OR, 2.5 [1.1-5.5]; P = .03), and chronic obstructive pulmonary disease (OR, 1.7 [1.04-2.9]; P = .04). A risk prediction model based on these criteria produced a C statistic of 0.69 in the prediction cohort and 0.76 in the validation cohort and a Hosmer-Lemeshow goodness of fit of 0.62 and 0.14, respectively. A score of <3 of 9, corresponding to a <5% probability of transfusion, would avoid preoperative type and cross in 86% of patients. Of the 4203 patients (86%) with a hematocrit >36%, only 6 (0.1%) had a risk score of >3.
Perioperative transfusion for EVAR is becoming increasingly uncommon and is predicted well by a transfusion risk score or simply a hematocrit of <36%. Application of this risk score would avoid unnecessary type and cross in the majority of patients, leading to significant savings in both time and cost.
在择期血管内动脉瘤修复术 (EVAR) 之前,通常会常规开处术前血型和交叉配血检查,但这种做法的成本很高,且很少需要输血。因此,我们旨在通过对患者进行输血风险分层,确定一个仅进行血型和交叉配血检查就足够的患者群体。
我们查询了国家外科质量改进计划 (NSQIP) 的靶向血管模块,获取了 2011 年至 2015 年间所有择期 EVAR 的数据。我们仅纳入了肾下型动脉瘤,排除了破裂性动脉瘤和术前 72 小时内输血的患者。三分之二的病例被随机分配到模型推导队列,三分之一的病例分配到验证队列。我们使用逻辑回归创建并随后验证了一个用于预测手术前 24 小时内(包括术中)输血的风险模型。
2011 年至 2015 年间,共有 4875 例患者接受了择期肾下型 EVAR 治疗,其中仅 221 例(4.5%)在术后 24 小时内输血。在此期间,输血的频率呈单调下降趋势,从 2011 年的 6.5%降至 2015 年的 3.2%。与输血独立相关的因素包括术前血细胞比容<36%(比值比 [OR],3.4 [95%置信区间,2.1-5.4];P<0.001)、主动脉直径(每增加 1 厘米:OR,1.2 [1.03-1.4];P=0.02)、术前依赖性功能状态(OR,2.5 [1.1-5.5];P=0.03)和慢性阻塞性肺疾病(OR,1.7 [1.04-2.9];P=0.04)。基于这些标准的风险预测模型在预测队列中的 C 统计量为 0.69,在验证队列中的 C 统计量为 0.76,Hosmer-Lemeshow 拟合优度分别为 0.62 和 0.14。评分<3(对应<5%的输血概率)可避免 86%的患者进行术前血型和交叉配血检查。在 4203 名(86%)血细胞比容>36%的患者中,仅有 6 名(0.1%)的评分>3。
EVAR 的围手术期输血越来越少见,输血风险评分或简单的血细胞比容<36%可很好地预测输血。应用该风险评分可以避免对大多数患者进行不必要的术前血型和交叉配血检查,从而在时间和成本方面带来显著节省。